DXCM241227C67000
- 0.00
- 0.000.00%
DexCom Newsroom
Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Dexcom (DXCM)
DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Benzinga Market Summary: S&P Rises On PCE Data, Novo Nordisk Falls On Weight Loss Data, Diabetes Stocks Rise
DexCom, Insulet, Tandem Benefit From Novo Nordisk CagriSema Data
Shares of Glucose Monitoring Stocks Are Trading Higher Following Weaker-than-expected Weight Loss Data From Novo Nordisk.
Oura Raises $200M With Investment From Dexcom
Oura Boosts Valuation to $5.2B in Latest Funding Round
Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement
DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
AI-Driven Glucose Biosensing: Dexcom's (DXCM) Path To A Comeback
Bernstein Maintains DexCom(DXCM.US) With Buy Rating, Raises Target Price to $150
Dexcom's Over-the-counter Glucose Monitor Now Offers Users an AI Summary of How Sleep, Meals and More Impact Sugar Levels
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
Express News | Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (Cgm) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 Cgm
Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM
Is Dexcom, Inc. (DXCM) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Worst Performing Stocks for Tax Loss Selling – Wolfe
Peering Into DexCom's Recent Short Interest
The Nasdaq 100 is about to adjust, and these 11 companies may see a 50% increase in upside potential.
As the annual adjustment of the NASDAQ 100 Index approaches, a group of potential stocks is preparing to make their debut. This adjustment not only brings prestige to these companies but may also trigger a large-scale inflow of capital, further driving up stock prices.